Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 10, 2009

Rosetta Genomics Taps Warnex as Canadian Distributor for Cancer Diagnostics

  • Warnex Medical Laboratories signed an exclusive distribution agreement in Canada for three currently available tests from Rosetta Genomics. Samples will be sent from Canada to Rosetta Genomics’ Philadelphia-based CLIA-certified laboratory for analysis.

    Warnex will distribute miRview™ mets, which identifies the primary tumor site in patients presenting with metastatic cancer and those with cancer of unknown primary. miRview™ squamous, which differentiates squamous from nonsquamous, non-small-cell lung cancer, is also included in the agreement. Finally, Warnex will distribute miRview™ meso, which distinguishes mesothelioma from other carcinomas in the lung.

    “This agreement joins our existing contracts with Prometheus Laboratories in the U.S. and with Teva Pharmaceutical in Israel and Turkey,” notes Ronen Tamir, chief commercialization officer at Rosetta Genomics.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »